子宮内膜症治療薬の世界市場2016-2020

◆英語タイトル:Global Endometriosis Drugs Market 2016-2020
◆商品コード:IRTNTR9808
◆発行会社(調査会社):Technavio
◆発行日:2016年7月8日
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、子宮内膜症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、子宮内膜症治療薬の世界市場規模及び予測、種類別分析、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About the Endometriosis Market
Endometriosis is a common health condition in women where the endometrial tissue, which is found in the lining of the uterus, appears and grows outside the uterine cavity. The endometrial tissue is shed from the body during menstruation.
The tissue growing outside the uterine cavity is called endometrial implants. Endometriosis can also occur in the fallopian tubes, ovaries, pelvic cavity, vagina, cervix, and bladder. In rare cases, it has been reported in other parts of the body such as the lungs, brain, and skin. These implants are usually benign in nature. Women of reproductive age are often affected by this condition.
Endometriosis often occurs due to retrograde menstruation, where the menstrual blood flows back into the pelvic cavity instead of leaving the body. This then adheres to the surface of the bladder, ovaries, or rectum and continues to grow or thicken over the course of each menstrual cycle.

Technavio’s analysts forecast the global endometriosis market to grow at a CAGR of 2.05% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global endometriosis market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of approved and off-label branded and generic drugs used for the treatment and prevention of endometriosis and related pain. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Endometriosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• AstraZeneca
• Bayer HealthCare
• Pfizer

[Other prominent vendors]
• Addex Therapeutics
• Astellas Pharma
• Debiopharm
• ElexoPharm
• Endoceutics
• Euroscreen
• Forendo Pharma
• Isifer
• Kissei Pharmaceutical
• Neurocrine Biosciences
• Nippon Shinyaku
• ObsEva
• Orphagen Pharmaceuticals
• Philogen
• PregLem
• Repros Therapeutics
• Roivant Sciences
• SK Chemicals
• Speciality European Pharma
• SYNG Pharmaceuticals
• Takeda
• United Pharmaceuticals
• ValiPharma

[Market driver]
• Increased adoption of OCPs
• For a full, detailed list, view our report

[Market challenge]
• Surgeries as primary treatment option
• For a full, detailed list, view our report

[Market trend]
• Increased focus on intrauterine devices (IUDs)
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Endometriosis: An overview

PART 05: Pipeline analysis
• Pipeline molecules based on their mechanism

PART 06: Key buying criteria for endometriosis drugs

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by type of therapy
• Hormone therapy
• Market size and forecast
• Pain medications
• Market size and forecast

PART 09: Market segmentation by ROA
• Oral
• Parenteral
• Intrauterine systems
• Nasal spray

PART 10: Geographical segmentation
• Global endometriosis drugs market by geography 2015-2020
• Endometriosis drugs market in Americas
• Endometriosis drugs market in EMEA
• Endometriosis drugs market in APAC

PART 11: Market drivers
• Recurrence of endometriosis
• Increased adoption on OCPs
• Ineffective existing therapies leading to high unmet need

PART 12: Impact of drivers

PART 13: Market challenges
• Poor compliance rates leading to high dropouts
• Surgeries as primary treatment option
• Unavailability of proper diagnostic tools

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Replacement of GnRH agonists by GnRH antagonists
• Increased focus on IUDs
• Development of novel targets for treatment

PART 16: Vendor landscape
• Competitive scenario
• Key news
• Major upcoming vendors

PART 17: Key vendor analysis
• AbbVie
• AstraZeneca
• Bayer HealthCare
• Pfizer
• Other prominent vendors

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Pipeline portfolio: Global endometriosis drugs market
Exhibit 03: Segmentation of pipeline molecules in different stages of development
Exhibit 04: Segmentation of pipeline molecules based on their mechanism of action
Exhibit 05: Impact of GnRH antagonists on global endometriosis market
Exhibit 06: Competitive assessment of marketed and late-stage pipeline molecules
Exhibit 07: Key buying criteria for endometriosis drugs
Exhibit 08: Global endometriosis market snapshot: Developed and emerging markets 2015
Exhibit 09: Global endometriosis drugs market 2015-2020 ($ billions)
Exhibit 10: Opportunity analysis: Global endometriosis drugs market
Exhibit 11: Five forces analysis
Exhibit 12: Segmentation of global endometriosis drugs market by type of therapy
Exhibit 13: Global endometriosis market segmentation by type of therapy 2015
Exhibit 14: Hormone therapies market for endometriosis 2015-2020 ($ billions)
Exhibit 15: Pain medications market for endometriosis 2015-2020 ($ millions)
Exhibit 16: Global endometriosis market by type of therapy 2015-2020
Exhibit 17: Global endometriosis drugs market by geography 2015-2020
Exhibit 18: Segmentation of global endometriosis drugs market by geography 2015 and 2020
Exhibit 19: Segmentation of global endometriosis drugs market by geography 2015-2020 ($ millions)
Exhibit 20: Global endometriosis market by geography 2015-2020
Exhibit 21: Endometriosis drugs market in Americas 2015-2020 ($ millions)
Exhibit 22: Endometriosis prevalence in EMEA
Exhibit 23: Endometriosis drugs market in EMEA 2015-2020 ($ millions)
Exhibit 24: Endometriosis drugs market in APAC 2015-2020 ($ millions)
Exhibit 25: Impact of drivers
Exhibit 26: Impact of drivers and challenges
Exhibit 27: Market share of top vendors in global endometriosis drugs market 2015
Exhibit 28: Geographical presence of major vendors in global endometriosis market
Exhibit 29: Competitive scenario of vendors in global endometriosis market 2015-2020
Exhibit 30: Major upcoming vendors in global endometriosis market
Exhibit 31: AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions)
Exhibit 32: AbbVie: Geographical segmentation of Lupron by revenue 2015
Exhibit 33: AbbVie: Metrics analysis
Exhibit 34: AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions)
Exhibit 35: AstraZeneca: Geographic segmentation of Zoladex 2015
Exhibit 36: AstraZeneca: Metrics analysis
Exhibit 37: Bayer: YoY revenue and growth rate of Mirena 2013-2015 ($ billions)
Exhibit 38: Bayer HealthCare: Metrics analysis
Exhibit 39: Pfizer: YoY revenue and growth rate of Depo-Provera 2013-2015 ($ millions)
Exhibit 40: Pfizer: Metrics analysis



【掲載企業】

AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, Endoceutics, Euroscreen, Forendo Pharma, Isifer, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, ObsEva, Orphagen Pharmaceuticals, Philogen, PregLem, Repros Therapeutics, Roivant Sciences, SK Chemicals, Speciality European Pharma, SYNG Pharmaceuticals, Takeda, United Pharmaceuticals, ValiPharma.

【レポートのキーワード】

子宮内膜症、子宮内膜組織、子宮内膜症治療薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[子宮内膜症治療薬の世界市場2016-2020]販売に関する免責事項
★調査レポート[子宮内膜症治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆